Multimodality treatment strategies have changed prognosis of peritoneal metastases

Figure 6 Overall survival compared with disease-free survival for pseudomyxoma peritonei (A) and colorectal peritoneal carcinomatosis (B), treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, from the Netherlands[52] (with permission). Overall and disease-free survival of Pseudomyxoma Peritonei (A) and Colorectal PM (B), treated with CRS-HIPEC, from the Netherlands[52]: This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. CRS-HIPEC: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy; PM: Peritoneal metastases.